Cytochrome P450 3A inhibitors and inducers - UpToDate
CYP: cytochrome P450. * Mifepristone is a strong inhibitor of CYP3A4 when used chronically (eg, for hyperglycemia in patients with Cushing syndrome). The CYP3A4 inhibitory effect of a single 200 mg mifepristone dose is likely to be weaker and transient; however, specific data are lacking.
Inhibitors and inducers of P-glycoprotein drug efflux - UpToDate
Inhibitors of the P-gp drug efflux pump (also known as P-gp multidrug resistance transporter) listed above may increase serum concentrations of drugs that are substrates of P-gp, whereas inducers of P-gp drug efflux may decrease serum concentrations of substrates of P-gp.
UpToDate
A list of strong CYP3A4 inhibitors and inducers is provided as a separate table in UpToDate: Nefazodone is a strong inhibitor of CYP3A4; it can significantly elevate levels of co-administered medications that are dependent on CYP3A4 metabolism for clearance: 2 to 5 (parent) 2 to 33 (active metabolites)
Cytochrome P450 3A inhibitors and inducers - UpToDate
CYP: cytochrome P450. * Mifepristone is a significant inhibitor of CYP3A4 when used chronically (eg, for hyperglycemia in patients with Cushing syndrome), not in single-dose use. ¶ Classified as a weak inhibitor of CYP3A4, according to FDA system.
Cytochrome P450 3A inhibitors and inducers - UpToDate
For drug interaction purposes, the inhibitors and inducers of CYP3A metabolism listed above can alter serum concentrations of drugs that are dependent upon the CYP3A subfamily of liver enzymes, including CYP3A4, for elimination or activation.
Nirmatrelvir and ritonavir: Pediatric drug information - UpToDate
Management: Reduce brexpiprazole dose 50% with strong CYP3A4 inhibitors; reduce to 25% of usual if used with both a strong CYP3A4 inhibitor and a CYP2D6 inhibitor in patients not being treated for MDD, or strong CYP3A4 inhibitor used in a CYP2D6 poor metabolizer.
Rifamycins (rifampin, rifabutin, rifapentine) - UpToDate
2024年9月25日 · Rifamycins (most notably rifampin) are moderate to potent inducers of drugs undergoing metabolism by the cytochrome P450 enzyme system (notably CYP3A4), which can lead to reduced bioavailability and enhanced clearance of some coadministered medications.
Pharmacotherapy for insomnia in adults - UpToDate
2024年4月29日 · - Diagnostic criteria for chronic insomnia disorder (ICSD-3-TR) - Nonbenzodiazepine BZRAs in the management of insomnia in adults - Other drugs for the management of insomnia in adults - Safe medication prescribing practices for insomnia - US scheds controlled drugs - Benzodiazepines in the management of insomnia in adults - …
Statin muscle-related adverse events - UpToDate
2024年7月8日 · These genes include variation in cytochrome P450 genes including CYP3A4, CYP3A5, CYP2D6, and the vitamin D receptor gene. Genome-wide association studies – Examples include SLCO1B1 rs4149056 and other variants.
Serotonin-norepinephrine reuptake inhibitors: Pharmacology
2023年12月5日 · Serotonin-norepinephrine reuptake inhibitors (SNRIs) act primarily upon serotonergic and noradrenergic neurons, but have little or no effect upon cholinergic or histaminergic receptors . SNRIs include: